Please login or register to print this page.

VIEW TAGS

Articles tagged ‘bleeding’

October 30, 2015

New roadmap to improve AF management

The report from the 5th Atrial Fibrillation Network association (AFNET)/European Heart Rhythm Association (EHRA) consensus conference has been published recently in EP Europace,1 aiming to provide a roadmap to improve the quality of AF management.

read more

January 29, 2015

Meta-analysis confirms less bleeding risk with new oral anticoagulants

When compared with vitamin K antagonists (VKAs) administered to a target INR of 2.0 to 3.0, target-specific oral anticoagulants (TSOACs) are associated with less major bleeding, fatal bleeding, intracranial bleeding, clinically relevant non-major bleeding, and total bleeding, according to a study published recently in Blood.1

read more

December 19, 2014

Lower bleeding risk with apixaban versus VKAs

Apixaban is associated with a lower risk of bleeding than vitamin K antagonists (VKAs), which provides some reassurance regarding its safety, according to the authors of a meta-analysis published recently in the American Journal of Cardiology.1

read more

August 5, 2014

Apixaban versus warfarin and aspirin: results from AVERROES and ARISTOTLE

The efficacy and safety of apixaban compared with aspirin are consistent in subgroups of patients who have previously attempted but failed Vitamin K antagonist (VKA) therapy, irrespective of the reason for discontinuation, according to a study published recently in the European Heart Journal.1

read more

June 26, 2014

New oral anticoagulants and bleeding management

As new oral anticoagulants (NOACs) are being prescribed with increasing frequency, and patients are fully anticoagulated, although the risk of intracranial bleeding is reduced, there is still a risk of major haemorrhage. An article by Dr Raza Alikhan (University Hospital of Wales, Cardiff), published in the British Journal of Cardiology,1 provides an understanding of the metabolism and excretion of NOACs, as well as their effects on coagulation tests, which is paramount in the management of patients, particularly in emergency situations.

read more

March 28, 2014

ARISTOTLE: new analysis shows less bleeding and strokes with apixaban

The novel oral anticoagulant apixaban is associated with fewer intracranial haemorrhages compared with warfarin, as well as less adverse consequences following extracranial haemorrhage, according to a study published recently in the Journal of the American College of Cardiology.1 The study also showed a 50% reduction in fatal consequences at 30 days in cases of major haemorrhage with apixaban.

read more

June 25, 2012

In vitro approaches to reversal of anticoagulant, apixaban, explored

Three approaches may reverse the activity of the new oral anticoagulant apixaban, when a person needs emergency surgery, for example, according to laboratory research presented in the American Heart Association’s Emerging Science Series webinar.1

read more

Members Area

Log in or Register now.

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.